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ABSTRACT
Germline CDH1 mutations confer a high lifetime risk of
developing diffuse gastric (DGC) and lobular breast cancer
(LBC). A multidisciplinary workshop was organised to
discuss genetic testing, surgery, surveillance strategies,
pathology reporting and the patient’s perspective on
multiple aspects, including diet post gastrectomy. The
updated guidelines include revised CDH1 testing criteria
(taking into account ﬁrst-degree and second-degree
relatives): (1) families with two or more patients with
gastric cancer at any age, one conﬁrmed DGC; (2)
individuals with DGC before the age of 40 and (3) families
with diagnoses of both DGC and LBC (one diagnosis
before the age of 50). Additionally, CDH1 testing could be
considered in patients with bilateral or familial LBC before
the age of 50, patients with DGC and cleft lip/palate, and
those with precursor lesions for signet ring cell carcinoma.
Given the high mortality associated with invasive disease,
prophylactic total gastrectomy at a centre of expertise is
advised for individuals with pathogenic CDH1 mutations.
Breast cancer surveillance with annual breast MRI starting
at age 30 for women with a CDH1 mutation is
recommended. Standardised endoscopic surveillance in
experienced centres is recommended for those opting not
to have gastrectomy at the current time, those with CDH1
variants of uncertain signiﬁcance and those that fulﬁl
hereditary DGC criteria without germline CDH1 mutations.
Expert histopathological conﬁrmation of (early) signet ring
cell carcinoma is recommended. The impact of gastrectomy
and mastectomy should not be underestimated; these can
have severe consequences on a psychological, physiological
and metabolic level. Nutritional problems should be
carefully monitored.
INTRODUCTION
Worldwide, gastric cancer (GC) is the ﬁfth leading
cause of cancer and the third most common cause
of death from cancer, with an estimated number of
723 000 deaths annually.1 The vast majority of
GCs are sporadic, but it has now been established
that 1–3% of GCs arise as a result of inherited
cancer predisposition syndromes. These syndromes
include Li-Fraumeni syndrome,2–4 Lynch syn-
drome,5–7 Peutz-Jeghers syndrome,8–10 hereditary
breast and ovarian cancer,11 12 MUTYH-associated
adenomatous polyposis (MAP),13 familial aden-
omatous polyposis,14–16 juvenile polyposis syn-
drome17 18 and PTEN hamartoma tumour
syndrome (Cowden syndrome).19 The lifetime risk
of GC in these syndromes varies substantially
between populations studied, but is generally low.
Over 15 years ago, linkage analysis implicated
germline mutations in the CDH1 gene, encoding
the tumour-suppressor protein E-cadherin, as the
genetic cause of hereditary diffuse GC (HDGC).20
Heterozygous germline CDH1 mutations increase
lifetime risk of developing diffuse GC (DGC) and
lobular breast cancer (LBC). Criteria have been set
to select families eligible for screening of germline
CDH1 mutations, and they were updated in
2010.21 22 Not all families fulﬁlling these criteria
have mutations in CDH1, indicating that other
genes may also be involved in DGC predisposition.
Germline mutations in CTNNA1 were described in
three families that presented with DGC, one of
them fulﬁlled the 2010 HDGC criteria.23 24
Increasing awareness of HDGC and the rapid
advances in genetic diagnostic tools, endoscopic
modalities and the increasing use of laparoscopic
surgery led a group of clinical geneticists, gastroen-
terologists, surgeons, oncologists, pathologists,
molecular biologists, dieticians and patients’ repre-
sentatives from nine different countries to convene
a workshop in order to update the management
guidelines for this condition set in 2010 and to
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propose directions for future research. The workshop discus-
sions were focused on ﬁve major topics: (1) genetic counselling
and mutation analysis; (2) endoscopic surveillance and screening
of cancer; (3) risk-reduction surgery of the stomach and breasts;
(4) pathological specimen processing and diagnosis; and (5)
patients’ and dieticians’ perspective.
GENETIC COUNSELLING AND MUTATION ANALYSIS
Genetic evaluation of patients with HDGC
Genetic counselling is an essential component of the evaluation
and management of HDGC. The counselling process should
include a formal genetics evaluation by a cancer genetics profes-
sional with expertise in the ﬁeld. The evaluation should include a
detailed three-generation family pedigree, histopathological con-
ﬁrmation of DGC diagnoses and/or precursor lesions (in situ or
pagetoid spreading of signet ring cells) and a discussion on life-
time risks of developing DGC and LBC. Informed consent for
genetic testing is required. In the management of individuals
with a CDH1 mutation, a full multidisciplinary team (MDT)
should be involved comprising those with relevant expertise in
gastric surgery, gastroenterology, breast oncology, pathology, psy-
chosocial support and nutrition. Genetic testing can be offered
from the age of consent (and therefore will vary between coun-
tries, but will generally be around 16–18 years). Testing of
younger unaffected family members can be considered on a
case-by-case basis. Rare cases of clinically signiﬁcant DGC have
been reported in affected families before the age of 18,25 but the
overall risk of this disease before the age of 20 is low.26 27
Cancer risks in CDH1 mutation carriers
In a recent study, penetrance data for CDH1 mutation carriers has
been updated based on affected individuals, who presented clinically
with DGC or LBC, from 75 families with pathogenic CDH1 muta-
tions. Families with CDH1 missense mutations and families for
which no carrier test information was available were excluded from
this analysis. The cumulative risk of DGC for CDH1 mutation car-
riers by age 80 years is reported to be 70% for men (95% CI 59%
to 80%) and 56% for women (95% CI 44% to 69%). Furthermore,
the cumulative risk of LBC for women with a CDH1 mutation is
estimated to be 42% (95% CI 23% to 68%) by 80 years. There is
currently no evidence that the risk of other cancer types in indivi-
duals with a CDH1mutation is signiﬁcantly increased.24
Implications of counselling
Clinical geneticists (or other members of the MDT) should
inform the counselee about gastric surgery and options of surveil-
lance. Proven pathogenic CDH1 germline mutation carriers
should be advised to undergo prophylactic gastrectomy (for
more details, see the ‘Surgery’ section). Some patients may want
to delay prophylactic gastrectomy for personal and/or work-
related reasons. In these individuals, endoscopic surveillance,
described in detail under the ‘Endoscopic surveillance’ section,
should be considered in the interim. The management of patients
and families with clinical features suggestive of HDGC, but
without a germline CDH1 mutation, is not straightforward. We
advise intensive endoscopic surveillance in an expert centre for
ﬁrst-degree relatives of patients meeting criteria mentioned
in ﬁgure 1. This is also the case for patients and families who
Figure 1. Algorithm for management starting from clinical hereditary diffuse gastric cancer (HDGC) testing criteria, genetic testing, role of
endoscopy and gastrectomy. GC, gastric cancer; DGC, diffuse gastric cancer; LBC, lobular breast cancer; MLPA, multiplex-ligation probe
ampliﬁcation.
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carry a CDH1 variant with unproven deleterious effect.
Recommendations on breast cancer surveillance and therapy in
CDH1 mutation carriers can be found below.
Criteria for germline CDH1 mutation testing
The last guideline in 2010 broadened the clinical criteria to
select patients eligible for CDH1 mutation analysis. The detec-
tion rate of CDH1 mutations before 2010, using the guidelines
established in 1999,21 was reported to be 25–50%.27 28 Using
the new criteria, the CDH1 detection rate in countries with a
low incidence of GC has decreased to 10–18% (RS van der Post
et al, under revision, 2015).24 29 This decrease may also be
explained partly by the enrichment of large and highly sus-
pected families in studies published before 2010 (ie, ascertain-
ment bias). The detection rate is considerably higher in the New
Zealand Maori population and is likely higher in the
Newfoundland population, where a founder mutation has been
described.27 It should be noted that these criteria are designed
for countries with a low incidence of sporadic GC. Few small
series and case reports of individuals with CDH1 mutations
have been described in countries with a high incidence of spor-
adic GC; no large cohorts were examined systematically. In
small series of South Korea, Japan and Portugal, mutation detec-
tion rates of pathogenic germline CDH1 mutations in HDGC
and early-onset GC range between 8% and 15%.2 30–33
During the workshop, it was decided to merge the ﬁrst (‘Two
or more GC cases in a family, one DGC <50’) and second
(‘Three or more DGC cases regardless of age’) testing criteria
from the previous guideline22 into a new criterion: ‘Two or
more GC cases regardless of age, at least one conﬁrmed DGC’,
in ﬁrst-degree and second-degree relatives. The two other
testing criteria have not been changed. The revised criteria are
depicted in the upper panel of the box in ﬁgure 1. The revised
criterion now covers families for whom detailed pathology is
incomplete. However, as in the earlier criteria, conﬁrmed
intestinal-type GC cases are not part of HDGC and in these
families no CDH1 mutation analysis should be performed. To
properly assess whether a family meets the HDGC criteria, path-
ology reports and preferably review of gastric specimens by a
pathologist dedicated to GC are essential.
There are other families in which genetic testing may also be
considered (ﬁgure 1, lower panel). The presence of bilateral
LBC at young age (under the age of 50 years) or the presence of
multiple close relatives with LBC (at least two under the age of
50 years) may justify testing for CDH1 mutations.29 34 Testing
should also be considered in individuals with a personal or
family history of cleft lip/cleft palate and DGC.35 36
Furthermore, in cases where expert pathologists detect in situ
signet ring cells and/or pagetoid spread of signet ring cells in
the stomach, genetic testing should be considered since this is
rarely (if ever) seen in sporadic cases. Genetic testing should,
whenever possible, be initiated in an affected proband. If the
affected proband is deceased, frozen-ﬁxed or formalin-ﬁxed,
parafﬁn-embedded tissue (preferably normal, non-malignant
tissue) still may be available for CDH1 germline mutation
testing. In case tissue of an affected individual is not available or
of insufﬁcient quality to perform the test, testing of unaffected
relatives is acceptable. This should be performed preferably in at
least three ﬁrst-degree relatives simultaneously, thus increasing
the likelihood of detecting a CDH1 mutation. However, it has
to be made clear to the counselee that unaffected individuals
have only a 50% chance of having inherited a mutated CDH1
allele. The testing criteria still have to be met by the counselee’s
family. If no mutation is found in these cases, endoscopic
screening should be discussed with an expert gastroenterologist
on a case-by-case basis. Similarly, in small families with DGC or
in families where family history is unavailable, CDH1 mutation
screening should also be considered on a case-by-case basis.
Genetic testing: lab perspective
Genetic testing on blood or tissue for germline mutations
should be performed in certiﬁed molecular diagnostic laborator-
ies, for example, Clinical Laboratory Improvement Amendments
approved, ISO 15189 accredited or equivalent. CDH1 analysis
should include mutation analysis of the entire open-reading
frame, including intron–exon boundaries, as well as copy
number analysis of individual exons to detect intragenic exon
deletions or duplications. At present, analyses are mostly per-
formed by a combination of Sanger sequencing and Multiplex
Ligation-dependent Probe Ampliﬁcation. These techniques can
be replaced by next-generation sequencing if the approach used
fulﬁls the requirement of similar sensitivity.
To date, over 155 different germline CDH1 mutations have
been described, the majority pathogenic mutations and a
number of variants of uncertain signiﬁcance (RS van der Post
et al, under revision, 2015).24 The majority of the pathogenic
mutations are truncating and thus do not lead to a functional
protein. Large exonic deletions are relatively rare, with a fre-
quency of about 5%.37 38 CDH1 is a tumour suppressor gene
and therefore a somatic second hit is required for initiation of
tumour formation. The trigger and molecular mechanism by
which the second allele of CDH1 is inactivated appears to be
diverse and includes methylation, somatic mutation and loss of
heterozygosity.39–42
The identiﬁcation of germline CDH1 missense variants
requires additional studies to assess their putative pathogenicity.
A multidisciplinary approach combining familial and population
data, in silico analysis and in vitro analysis is currently used to
classify the variants as neutral or pathogenic.43–47 Genetic para-
meters such as mutation frequency in healthy control popula-
tions, co-segregation of the mutation within the pedigree and
recurrence of the mutation in independent families should be
considered as a ﬁrst approach.43 45 However, the low number of
individuals affected by the disease, the small size of the pedi-
grees and the absence of mutation hotspots (which prevents the
establishment of any correlation between the mutation site and
its functional consequence) are limitations of this approach.
In silico experiments predict the degree of conservation of a
speciﬁc nucleotide within species, the effect of missense variants
on splicing and also the putative impact of the variants on
protein structure.45 47 Still, in silico results should be carefully
interpreted because the degree of conservation among species of
each amino acid position is considered separately and does not
take into account possible compensatory effects of neighbouring
amino acids.45 47 Functional in vitro assays should be performed
in order to evaluate the impact of CDH1 missense alterations in
protein structure, trafﬁcking, signalling and, consequently, in
E-cadherin function.44 46 When compared with the cells expres-
sing wild-type E-cadherin, pathogenic missense mutants impair
the correct binding of key adhesion-complex regulators and
likely compromise normal E-cadherin localisation and stability
at the plasma membrane.46 48 As a consequence, disruption of
cell–cell adhesion and increased invasive behaviour may be
observed in the presence of pathogenic variants.44 46 To date,
49 germline CDH1 missense variants were reported for func-
tional evaluation to Institute of Molecular Pathology and
Immunology of the University of Porto (Portugal, reference
laboratory for functional characterisation of CDH1 missense
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variants for the International Gastric Cancer Linkage
Consortium), the majority being classiﬁed as deleterious and
thus possibly pathogenic (R Seruca, personal communication,
2014).
Panel sequencing
Penetrance estimates for CDH1 mutation carriers have been
derived from the study of highly ascertained HDGC families
and it is likely that the penetrance for mutations detected in
non-HDGC families will be lower. With the introduction of
next-generation sequencing-based gene panels, both in research
and diagnostic settings, CDH1 alterations may be found in
patients without a personal or family history of GC.49 50 In our
opinion, one should be very cautious in the interpretation of
coding variants identiﬁed in non-HDGC families, especially if
the alterations do not lead to a premature stop codon.
CDH1 mutation database
Currently, there is no international database containing all germ-
line CDH1 mutations and variants identiﬁed to date. A database
has been designed and is currently under construction with the
collaboration of the LOVD team. The variant database is avail-
able at http://www.LOVD.nl/CDH1. This database can be con-
sulted to assess whether a given CDH1 mutation has been
found by others and whether it has been considered deleterious
and likely disease-causative or not based on population data,
segregation analysis, in silico analysis and in vitro functional
analysis, and/or recurrence in several individuals/families. We
advise researchers and clinicians to submit unpublished muta-
tions and variants to the database (contact C Oliveira, carlao-
l@ipatimup.pt), together with the requested information on
families/patients and mutations. The publication/submitter of
every mutation will always be referred to in the database.
Psychosocial effects of counselling
Even though it is well recognised that many individuals will
beneﬁt from genetic counselling and testing for hereditary
cancer in general, there have also been reports that it may
induce a number of psychosocial problems. In a review on indi-
viduals requesting genetic counselling and testing for hereditary
cancer syndromes, six dominant problem areas were identiﬁed:
(1) coping with cancer risk; (2) practical problems (such as
obtaining life insurance/loans and employment when found to
be a mutation carrier); (3) family-related problems (eg, commu-
nication problems with family members, feeling responsible for
family members); (4) children-related problems (eg, concerns
for children having increased risk, fear of leaving young chil-
dren); (5) living with cancer (eg, fear of developing cancer, pain
about the loss of family members) and (6) emotions (eg, anxiety,
anger, feelings of loss, but also relief and reassurance).51 These
topics, when applicable, should be addressed during the coun-
selling sessions.
Pregnancy and assisted reproduction
Although scientiﬁc data are lacking concerning timing of
prophylactic gastrectomy and family planning, it is entirely pos-
sible for women to give birth to a healthy child after gastrec-
tomy.52 Nutritional advice and follow-up with a dietician within
this context is essential.
Individuals from hereditary cancer families are frequently
concerned about the transmission of their predisposition of
cancer to their children.53 54 Healthcare professionals, including
geneticists and psychosocial workers, will be increasingly
involved in discussions and decisional counselling regarding
reproductive options in families with a known cancer predispos-
ing mutation such as CDH1. In the past decades, genetic testing
for hereditary cancers before birth has become available
through prenatal diagnosis (PND) and preimplantation genetic
diagnosis (PGD).55 We recommend that carriers of a CDH1
mutation with a desire to have children should be informed
about all reproductive options, including PND and PGD.
Future research: other genes involved in HDGC
predisposition
Currently, three families that meet the new criteria have been
described to carry germline CTNNA1 mutations.23 24 Even
though these families show a clinical picture similar to that of
CDH1 mutation-positive families,23 insufﬁcient data are available
to make a statement on disease penetrance. Given the functional
connection between the two genes, they may represent a geno-
copy. Mutation carriers could be given the option of prophylactic
total gastrectomy (PTG) and other cancer prevention measures
recommended for HDGC families, but with the precaution that
such advice is being given based on very limited data.
Other families have recently been described with BRCA2 and
PALB2 mutations;24 however, we recommend that these families
are managed no differently than other families with such muta-
tions according to national guidelines. It is likely that other
HDGC-associated genes will be discovered through whole
exome, genome or other unbiased next-generation-sequencing
empowered methodologies. Indeed, using a combination of this
approach and linkage analysis, mutations in MAP3K6 have
recently been described.56 More needs to be understood about
families with MAP3K6 mutations before they could be used to
stratify risk in families. Until such data are available, a cautious
approach in which all ﬁrst-degree relatives of mutation carriers
are followed is recommended. Without multiple mutation-
positive families for newly identiﬁed genes, it will be extremely
difﬁcult to ascribe pathogenicity to such mutations and to
develop management guidelines.
SCREENING AND SURVEILLANCE
Gastric endoscopic screening and surveillance
To clarify the terminology, we consider that individuals having
endoscopy who do not know their mutation status or those who
do not have a proven pathogenic CDH1 mutation undergo
screening whereas mutation-positive individuals undergo surveil-
lance. The consensus reached at the workshop was that indivi-
duals who tested positive for a pathogenic germline CDH1
mutation should be advised to consider prophylactic gastrec-
tomy, regardless of endoscopic ﬁndings. However, the timing of
surgery may vary according to the preferences and age, as well
as the physical and psychological ﬁtness of the individual. In
patients proceeding for gastrectomy, a baseline endoscopy
should be performed prior to surgery to look for macroscopic
tumour as this may alter the treatment plan. This endoscopy is
also performed to ensure that there is no other coincidental
pathology, such as Barrett’s oesophagus, which may alter the
extent of the resection. When the stomach is macroscopically
normal, the information on microscopic disease foci is useful to
compare with ﬁndings in the surgical resection specimen and
hence to increase knowledge on the likelihood of endoscopic
detection of microscopic lesions.
For individuals with a CDH1 mutation in whom gastrectomy
is not currently being pursued (eg, through patient choice or
existence of physical or psychological comorbidity), regular
endoscopy should be offered. In patients declining surgery, sur-
veillance can have the advantage of helping individuals to come
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to a decision about the need for gastrectomy when microscopic
foci of signet ring cells are detected. However, patients should
be aware that delaying surgery can be a hazardous decision.57
The management of individuals with a CDH1 variant of
uncertain signiﬁcance and those in whom no mutation can be
identiﬁed in the family is not straightforward. We would recom-
mend that intensive endoscopic surveillance in an expert centre
should be offered to these families who fulﬁl the HDGC cri-
teria. Endoscopic screening has a valuable role in guiding clin-
ical decision making and in one case series lesions were detected
in 2/7 CDH1 mutation-negative individuals (1/5 families).57
Speciﬁcally, any malignant lesions detected endoscopically
would prompt a referral for gastrectomy. However, all patients
undergoing endoscopy for HDGC should be informed that,
given the very focal and often endoscopically invisible nature of
these lesions, it is quite possible that lesions will not be detected
by random biopsies.
HDGC endoscopy protocol
Endoscopy should be performed in centres with an experienced
MDT. However, it is appreciated that sometimes this is not prac-
tical for individuals who have to travel long distances. In this
case, a local endoscopist in consultation with an expert centre
on the endoscopy protocol and review of histology may be a
helpful alternative.
As noted above, the optimal frequency of endoscopy is not
known. Based on current experience, it is recommended that
individuals should be offered annual endoscopy. The bleeding
risk may be slightly higher than for other indications since more
biopsies are taken. Therefore, it is recommended that the local
high-risk endoscopy protocol is followed such that, if possible,
anticoagulants (eg, warfarin and clopidogrel) are stopped prior
to the procedure. The endoscopy should be performed using a
white light high deﬁnition endoscope in a dedicated session of
at least 30 min to allow for careful inspection of the mucosa on
repeated inﬂation and deﬂation and for collection of biopsies.
The mucosa should be thoroughly washed before examination
with a combination of mucolytics (N-acetylcysteine) and anti-
foaming agent (such as simethicone) mixed with sterile water.
This washing is ideally done via a pump operated by a foot
pedal. The macroscopic appearances of the gastric mucosa and
any focal visible lesions should be recorded using still images or
video for future reference and speciﬁcally sampled for histology
prior to the collection of random biopsies.
Prior to examination for small foci, the stomach should be
adequately inﬂated and deﬂated to check distensibility. Poor dis-
tensibility should raise alarm for a submucosal inﬁltrative
process like linitis plastica. When this is the case, biopsies
should be taken and further imaging such as a high-resolution
multidetector CT scan combined with endoscopic ultrasonog-
raphy is suggested to visualise the gastric wall layers. No object-
ive measures of distensibility are currently available, and this is
an area that may warrant future research.
Although an association between Helicobacter pylori infection
and HDGC has not been proven, it is important to test for H.
pylori to document the prevalence of infection. Since H. pylori
is a WHO class 1 carcinogen, it is agreed that when individuals
are infected it should be eradicated, especially in those opting
for surveillance. A rapid urease test is the preferred test at base-
line, and additionally, it is recommended to take random biop-
sies from the antrum and the corpus due to patchy colonisation,
especially in the presence of acid suppression.
Due to the tiny foci of signet ring cells, which can only be
recognised by microscopy, multiple biopsies are required to
maximise the likelihood of diagnosing them.39 The anatomical
gastric localisation in which foci are identiﬁed varies between
studies; reasons for this remain to be clariﬁed but may include
environmental factors or differences in the molecular pathogen-
esis.39 57–65 Therefore, it is recommended that any endoscopic-
ally visible lesions are biopsied including pale areas.
Additionally, random sampling should be performed comprising
ﬁve biopsies taken from each of the following anatomical zones:
pre-pyloric area, antrum, transitional zone, body, fundus and
cardia. A minimum of 30 biopsies is recommended as described
in the Cambridge protocol (see online supplementary protocol
1).22 Even though this will still lead to sampling bias due to the
large gastric surface area, taking more biopsies is not feasible in
practice.65 The biopsies may be taken using a standard forceps,
ideally with a spike as this will seize the lamina propria in which
signet ring cell foci are present. In the case of a well-deﬁned
visible lesion, an endoscopic mucosal resection can be helpful to
achieve a more reliable histopathological specimen to document
the degree of invasion. However, this should be done for diag-
nostic rather than therapeutic purposes in view of the multifocal
nature of the lesions.
Special mention should be given to pale areas since these are
more likely to harbour microscopic foci of abnormal cells,
although they lack speciﬁcity leading to false positives (ﬁgure 2).66
Recent data also suggest that these areas are visible on careful
examination by white light, but narrow band imaging may make
them easier to visualise (A Cats, personal communication, 2014).
As noted in the previous guidelines, chromoendoscopy with
Congo-red and methylene blue is no longer recommended due to
concerns over toxicity.66 Virtual chromoendoscopy using auto-
ﬂuorescence and trimodal imaging does not seem to confer much
additional beneﬁt over white light.57 In order to maximise the
yield from endoscopy, specialist histopathology reporting is essen-
tial and the guidelines outlined in the pathology section below
should be followed.
Endoscopic surveillance of colorectal cancer
Although there are case reports of colorectal and appendiceal
signet ring cell carcinomas (SRCCs) in CDH1 mutation car-
riers,26 67–70 there is currently no evidence to suggest that the
risk of colorectal cancer in CDH1 mutation carriers is signiﬁ-
cantly elevated and there are insufﬁcient data to give recommen-
dations on colorectal cancer screening. In CDH1 mutation
families in which colon cancer is reported in mutation carriers,
information should be collected concerning the age at diagnosis,
whether the affected member(s) and ﬁrst-degree or second-
degree relatives are mutation carriers and whether the histopath-
ology showed a mucinous component and/or signet ring cells.
For such families, enhanced colonoscopy screening should be
considered at age 40 or 10 years younger than the youngest
diagnosis of colon cancer, whichever is younger, and repeated at
intervals of 3–5 years. In the absence of a family history, the
national guidelines for colon cancer screening should be fol-
lowed. It is imperative that data on colonoscopic screening in
these individuals are collected so that these guidelines can be
based more on evidence than on specialist opinion in the future.
Breast cancer surveillance
Knowledge about breast cancer risk in HDGC has slowly
advanced since ﬁrst reported in 2000,26 yet evidence is not suf-
ﬁcient such that recommendations can be made of comparable
strength as in BRCA1/2. Genotype–phenotype correlations may
eventually show some HDGC families do not have an increased
LBC risk, but at present it should be assumed all women with a
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CDH1 mutation are at risk. When informing women with
CDH1 mutation about the role of breast surveillance versus
prophylactic mastectomy to manage their risk, the consultation
covers similar territory as in BRCA1/2. There are, however,
some important differences that must be carefully explained.
Invasive LBC, the type that typically occurs in HDGC, makes
up 5–15% of sporadic breast cancer. Invasive ductal cancer
occurs in 85–95% of sporadic breast cancer and in BRCA1/2
cases.71 In contrast to ductal breast cancer, E-cadherin-deﬁcient
LBC invades in sheets or cords of cells, typically in single ﬁle,
and does not form a well-deﬁned mass. Studies comparing dif-
ferent radiological modalities in sporadic LBC show sensitivity
on mammography ranges from 34% to 92%.71 Bilateral breast
MRI needs to be part of the protocol in CDH1 mutation car-
riers. Given the fact that mammography has a low sensitivity for
LBC, synchronous mammography at the time of MRI may add
little. We therefore recommend annual breast MRI (which can
be combined with mammography) starting at age 30 in women
with a CDH1 mutation. An oncologist or breast surgeon should
guide breast surveillance. Annual clinical breast examination and
breast cancer awareness from the patient and her physicians are
essential.
Future research on gastric and breast surveillance
In light of emerging endoscopic technologies, such as narrow
band imaging, blue laser imaging, I scan, autoﬂuorescence
imaging, IHb-enhancement and confocal endomicroscopy,72
research is required to further study the optimal methods for
endoscopic monitoring of individuals at risk for DGC. Given
the rarity of this condition, these need to be multicentre studies
with strictly deﬁned protocols. In addition, it is likely that the
multiple biopsy protocol leads to scarring that can masquerade
as pale areas (ﬁgure 2D). It would therefore be very valuable to
compare the yield of a targeted biopsy approach only with the
current Cambridge protocol, which also includes multiple
random biopsies. Such studies could also inform on the interob-
server variation in the identiﬁcation of pale areas and help
deﬁne features indicative of a signet ring cell focus. An
endoscopic atlas created by endoscopists performing regular
endoscopies on CDH1 mutation carriers would be very useful
to help standardise protocols and improve lesion recognition.
There are no studies speciﬁcally addressing screening for
LBC. Trials on breast screening in the general population and
MRI screening in high-risk groups or BRCA1/2 are informative
but do not directly extrapolate to the screening scenario in
HDGC. The outcomes of the above-stated recommendations of
breast surveillance in HDGC women should be further pro-
spectively investigated.
GASTRECTOMY AND MASTECTOMY
Prophylactic gastrectomy: indications for and timing of
surgery
Prophylactic gastrectomy should be strongly advised in carriers
of a proven pathogenic germline CDH1 mutation. Some argue
that the term ‘prophylactic gastrectomy’ is inaccurate and favour
the term ‘risk reduction gastrectomy’ because most mutation
carriers already have microscopic SRCCs at the time of their
surgery. Total gastrectomy for these patients, however, com-
pletely eliminates their risk of GC and is truly prophylactic in
terms of preventing their death from invasive GC.
The optimal timing of prophylactic gastrectomy is unknown
and is usually highly individualised. Since this surgery has major
impact on the quality of life, the decision to undergo prophylac-
tic gastrectomy should be well informed, balanced, prepared
and timed. Decisional counselling, outweighing the pros and the
cons of the intervention is essential. The current consensus is
that the procedure should be discussed and offered to patho-
genic germline CDH1 mutation carriers in early adulthood, gen-
erally between ages 20 and 30.58 Based upon the physical ﬁtness
of the mutation carrier and of surgery-related complications,
prophylactic gastrectomy at an age >75 should be carefully con-
sidered. Family phenotype, especially age of onset of clinical
cancer in probands, should be taken into account. There is
likely to be a dormant period in which the signet ring cell
adenocarcinoma does not spread or progress since they have a
low proliferative index and the age of prophylactic gastrectomy
Figure 2 Pale areas in gastric
mucosa of a patient with a germline
CDH1 mutation harbouring signet ring
cell focus during white light endoscopy
(A) and narrow band imaging (B). H&E
stain of biopsy specimen with signet
ring cells (C). Scar area after biopsy
during previous endoscopy (D).
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is generally lower than that of overt cancer.39 This may explain
why so many individuals are found to have T-1 N-0 stage
tumours after prophylactic gastrectomy.73 Patients who develop
symptomatic, widely invasive DGC have a poor prognosis with
as few as 10% having potentially curable disease.74 Even if
potentially curable, 5-year survival rate still does not exceed
30%.75 As our understanding of the natural history of mucosal
SRCC improves, it may be possible to safely postpone prophy-
lactic gastrectomy in some patients, but until such time it is
safer to recommend surgery early in adult life. This has implica-
tions for the long-term follow-up of patients with prophylactic
gastrectomy and reinforces the need for MDTs to care for these
patients for the rest of their lives, similar to patients who have
undergone bariatric malabsorptive surgery for obesity.76
Operation details
The requisite operation is a total gastrectomy with Roux-en-Y
reconstruction, ensuring that the jejunojejunal anastomosis is at
least 50 cm distal to the oesophagogastric anastomosis, to
reduce the risk of biliary reﬂux. The proximal resection line
must be across the distal oesophagus containing squamous epi-
thelium to ensure that no gastric cardiac mucosa is left behind.
This can be conﬁrmed by frozen section or examination of the
opened resection specimen in operating room, and can be
guided by the use of on-table endoscopy to mark the squamo-
columnar junction during the surgery.
The optimal extent of lymph node dissection (LND) in
prophylactic gastrectomy is controversial.77 Lymph node metas-
tases are not reported in asymptomatic CDH1 mutation carriers
with negative preoperative surveillance biopsies or small foci of
pT1a intramucosal carcinoma. Among patients with early-stage
intestinal adenocarcinoma of the stomach, the frequency of
lymph node metastasis in patients with early intramucosal
(pT1a) tumours is 2–5%,78–81 and up to 6% in the undifferenti-
ated or diffuse types.78 80 In pT1b tumours, with invasion of the
submucosal layer, lymph node metastases are found in 17–28%,
increasing with the depth of submucosal invasion.80 81 The
majority of patients undergoing prophylactic gastrectomy for
HDGC will have at least T1a cancers. Because a preoperative gas-
troduodenoscopy cannot exclude the presence of T1b lesions
with their higher risk of metastases during the operation, a D1
LND (with the inclusion of lymph node stations 1–7) is
reasonable.
The formation of a jejunal pouch may improve eating for the
ﬁrst year after surgery, but, as yet, prospective trials comparing
pouch to straight Roux-en-Y reconstruction have not convin-
cingly demonstrated signiﬁcant long-term beneﬁts to justify the
routine application of this more complex reconstructive proced-
ure.82 Surgeons should therefore use the reconstruction they are
most familiar with. This also applies to whether the preferred
surgical approach is open or laparoscopic.77 83 There are poten-
tial advantages of laparoscopic gastrectomy with reduced
wound pain and faster overall return to full activities, but con-
clusive evidence for the superiority of this approach is still
lacking. Any surgeon proposing to do a laparoscopic PTG must
be able to reassure the patient that this is without additional risk
compared with open surgery.
Prophylactic mastectomy
Prophylactic mastectomy is not routinely recommended but may
be a reasonable option for some women. Literature about
prophylactic mastectomy in HDGC is scarce, and it is reason-
able to consider prophylactic mastectomy on a case-by-case basis
taking into account the family pedigree. National guidelines for
high-risk women should be followed with respect to chemopre-
vention using selective oestrogen receptor modulators or aroma-
tase inhibitors.
HISTOPATHOLOGY
Histopathology of biopsies from individuals suspected for
HDGC
Biopsies of individuals with a family history of DGC that are
endoscopically screened by the Cambridge protocol should be
examined thoroughly. The biopsies should be stained for H&E
at three levels and periodic acid–Schiff-diastase (PAS-D) as
standard. All lesions should be recorded. Biopsies from potential
carriers of a CDH1 mutation need careful evaluation by a path-
ologist with experience in the pathology of HDGC. In mutation
carriers, the detection of speciﬁc lesions may support a decision
towards prophylactic gastrectomy. In individuals without known
gene defects, the detection of such lesions may be used as an
additional argument that the patient is at high risk of developing
cancer and that a prophylactic gastrectomy should be discussed.
The speciﬁc lesions in HDGC are tiny foci of typical signet ring
cells sometimes admixed with a low number of smaller atypical
cells in the lamina propria without inﬁltration beneath the mus-
cularis mucosa (see ﬁgure 3A–D). The two preinvasive lesions
of SRCC are (1) in situ SRCC, corresponding to the presence of
signet ring cells with hyperchromatic and depolarised nuclei
within the basal membrane of a gland replacing the normal cells
of the gland; and (2) pagetoid spread of a row of signet ring
cells below the preserved epithelium of glands and foveolae,
and also within the basal membrane (see ﬁgure 4A, B).84
Criteria for the identiﬁcation of signet ring cell lesions should
be strictly followed in order to diminish the risk of overdiagnosing
non-speciﬁc changes and to distinguish them from lesions that
mimic SRCC or precursor lesions. In the gastrointestinal tract,
various benign ‘signet cell-like changes’ may mimic SRCC (see
online supplementary ﬁgure S1).85–88 Therefore, conﬁrmation of
focal signet ring cell lesions in the stomach by a histopathologist
with experience in this area is strongly recommended.
Histopathology of prophylactic gastrectomy: classiﬁcation of
microscopic foci and determination of signiﬁcance
Macroscopic examination and sampling of prophylactic gastrec-
tomies should follow speciﬁc protocols that can be found in
online supplementary protocol 2. The histological examination
should be made using a checklist, focusing on the items listed in
table 1.
Nearly all gastrectomies (data from >100 PTG cases pub-
lished) exhibit tiny mucosal foci of SRCC or in situ signet ring
cells, although sometimes these were only discovered after
careful review by a pathologist with experience in this
ﬁeld.25 36 39 59–64 77 91 92 There are numerous T1a carcinoma
foci but only a low number of in situ carcinoma lesions, suggest-
ing that invasion of the lamina propria by signet ring cells may
occur without a morphologically detectable in situ carcin-
oma.63 93 It is essential that the location of biopsies within gas-
trectomy specimens is speciﬁcally reported to learn more about
the distribution of early HDGC in the stomach.
Surgical margin status must conﬁrm that there is no residual
gastric mucosa and tumour at the margins. However, oesopha-
geal cardiac-type glands (presumably normal constituents) are
diffusely scattered in the lamina propria through all levels of the
oesophagus. The risk to develop SRCC in these glands is
unknown but has not been reported.94 Also, metaplastic and
heterotopic gastric mucosa can be seen elsewhere in the gastro-
intestinal tract. In a prophylactic gastrectomy series of 19
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patients, three cases (16%) showed heterotopic gastric mucosa
in the duodenum, and mucosal SRCC was observed in one of
them (RT van der Kaaij et al, unpublished data, 2014).
Background changes in the gastric mucosa of prophylactic
gastrectomy specimens encompass mild chronic gastritis, some-
times displaying the features of lymphocytic gastritis. Foveolar
hyperplasia and tufting of surface epithelium, focally with
globoid change, is also a frequent ﬁnding and, in some areas,
vacuolisation of surface epithelium is very striking; however,
this does not seem to be a speciﬁc ﬁnding.28 36 63 93 Intestinal
metaplasia and H. pylori infection are absent in most prophylac-
tic gastrectomies described to date.
Histopathology: advanced HDGC
Like sporadic DGC, advanced HDGC predominantly presents
as linitis plastica with diffuse inﬁltration of the gastric wall.
Histology can show mainly or exclusively signet ring cells;
however, more often these tumours are composed of a pleo-
morphic neoplastic inﬁltrate with a small subset of or without
classic signet ring cells (poorly cohesive carcinoma). In a minor-
ity of cases, tumour cells are arranged in small aggregates, some-
times rosettes or glandular-like structures. A component of
extracellular mucin may also be present, in which the neoplastic
cells ﬂoat. Although there are no speciﬁc morphological
characteristics indicating the hereditary nature of the tumour,
in situ lesions and pagetoid spread of signet ring cells in the sur-
rounding normal mucosa are important clues to the diagnosis.
Review of gastric specimens of 103 HDGC families without
germline CDH1 mutations showed a similar morphology com-
pared with the advanced germline CDH1 mutation-related car-
cinomas (van der Post et al, unpublished data, 2014). Typical
in situ lesions or pagetoid spread of signet ring cells, however,
were not detected in these patients.
Histopathology: LBC
The association of LBC and germline CDH1 mutations was ﬁrst
reported by Keller et al.95 Large series of the histopathological
ﬁndings in (prophylactic) mastectomies of CDH1 mutation car-
riers are not reported. Kluijt et al36 described bilateral wide-
spread foci of lobular carcinoma in situ in prophylactic
mastectomies of two female patients with germline CDH1
mutations. There are no unique histopathological ﬁndings
reported in (prophylactic) mastectomy specimens that can be
used to distinguish these (pre-)malignancies from sporadic
LBCs. However, only few patients opt for prophylactic mastec-
tomy and these mastectomy specimens are generally not fully
embedded and examined.
Figure 3 Mucosal signet ring cell
carcinoma (pT1a) H&E (A), periodic
acid–Schiff-diastase (B), E-cadherin (C)
and cytokeratin staining (D) (original
magniﬁcations ×200).
Figure 4 Precursor signet ring cell
lesions: pagetoid spreading of signet
ring cells (A) and in situ signet ring
cell carcinoma (B) (H&E, original
magniﬁcations ×400).
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Use of immunohistochemical stains
Widely invasive DGC may be easily detected on H&E sections.
The use of histochemical stains for neutral mucins, such as
PAS-D, is useful for the detection or conﬁrmation of tiny intra-
mucosal carcinomas in which the neoplastic cells are dispersed
among preserved foveolae and glands. This should be per-
formed routinely in the examination of gastric biopsies taken
during endoscopy and in gastrectomies from patients with
HDGC.96 A cytokeratin stain can help to conﬁrm the epithelial
nature of the signet ring cells if there is any doubt. E-cadherin
immunoexpression can be reduced or absent in early gastric car-
cinomas, contrasting with the normal membranous E-cadherin
expression in adjacent non-neoplastic mucosa.39 40 97 In page-
toid spread and in situ carcinomas, E-cadherin immunoexpres-
sion can also be reduced or absent.63 However, E-cadherin
expression is not always reduced or absent; this depends on the
mutation type and speciﬁc mechanisms of inactivation of the
wild-type allele.40 In DGC of patients without germline CDH1
mutations, the expression pattern of E-cadherin is also often
reduced or absent. Therefore, E-cadherin staining should not be
used as a pre-screening method to select patients eligible for
germline CDH1 mutation analysis.
In patients that present with both LBC and DGC, either syn-
chronously or metachronously, a metastasis should be consid-
ered. Two primary tumours may be indicative for a hereditary
background, but this is not always the underlying reason.
Metastases from these tumours are often morphologically indis-
tinguishable.98 Breast-associated immunomarkers are ER,
BRST-2 and/or mammaglobin, while CK20 and HNF4A are
suggestive for GC.99 100
Centres of excellence for pathological diagnosis
The pathology of HDGC is unique but not easy to recognise.
Experience in this pathology is needed to provide high-quality
diagnosis, both in biopsies and in resection specimens. In order
to increase the experience of pathologists and the accuracy of
the diagnosis, especially of precursor lesions of HDGC, it
would be useful to build a virtual bank of the different types of
lesions observed in the setting of HDGC. Furthermore, the
working group agreed that the use of (scanned) slides to be sub-
mitted for evaluation by experienced pathologists in the ﬁeld
should be seriously considered.
It is pivotal to examine the full gastrectomy and full mastec-
tomy specimens of CDH1 mutation carriers to determine the
stage of cancer and additionally to better understand the pheno-
type and biology of this disease. Experience in the examination
of prophylactic gastrectomies for HDGC is quite limited in
most pathology departments due to the rarity of these surgical
specimens. Additionally, the routine workload of most centres is
incompatible with performing the detailed examination of hun-
dreds of sections typically obtained after totally embedding
these stomachs. In the event of a lack of pathologist experience
in dealing with these cases, or restricted time available due to
the pathologist’s workload and laboratory resources, the entire
formalin-ﬁxed gastrectomy or mastectomy specimen can be send
to an experienced pathology laboratory. An alternative option is
to totally embed the stomach or breast, perform H&E and
PAS-D stain on all blocks and send the slides and blocks to an
experienced centre for specialist pathology reporting. If these
alternative strategies are not feasible, and it is not possible to
totally embed the gastric or breast specimen, this should be
communicated to clinicians and the patient. Furthermore, in the
event of not ﬁnding foci of SRCC, the gastrectomy should not
be reported as negative for carcinoma, but as ‘no carcinoma
found in xx% of mucosa examined’.
Future research on molecular pathogenesis
A critical question that remains unanswered is how long early
lesions of HDGC can remain indolent until there is emergence
of clinical disease that may be rapidly progressive and lethal.
Continuing collection of data from patients who opt for endo-
scopic surveillance is essential to help answer this question.
Also, a thorough analysis of the mechanisms responsible for the
Table 1 Checklist for reporting of prophylactic gastrectomy specimens
1. Features of ≥pT1b carcinoma(s) Growth pattern (diffuse infiltration vs localised tumour)
Anatomic location (cardia, fundus, body, transitional zone, antrum)
Measurements
Histological type according to WHO89 and Laurén’s90 classifications
Lymphatic, venous and neural invasion (present or absent)
Tumour, node, metastases stage
2. Features of intramucosal precursor lesions and pT1a SRCC Number of lesions
Anatomic location (cardia, fundus, body, transitional zone, antrum)
Measurements
Aggressive features: pleomorphism, loss of mucin, spindle cells, small cells, mitoses
Stromal reaction related to lesions: desmoplasia; lymphocytic, eosinophilic
or granulomatous inflammatory reaction
Surgical margin status (proximal oesophageal, distal duodenal mucosa, including donuts),
to confirm there is no residual gastric mucosa and no tumour at margins.
Lymph node status
3. Non-neoplastic mucosa: changes more commonly seen in this condition Tufting/hyperplastic mucosal changes
Surface epithelial vacuolisation
Globoid change
4. Other findings in surrounding mucosa Inflammation (acute, chronic, erosion, ulceration)
Helicobacter pylori
Intraepithelial lymphocytes
Lymphoid infiltrates
Glandular atrophy
Intestinal metaplasia
Adenomatous dysplasia
SRCC, signet ring cell carcinoma.
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second hit inactivation of CDH1 in the very early lesions of
HDGC is necessary to deﬁne strategies for chemoprevention.
The molecular background of patients with HDGC and
without CDH1 mutations remains to be clariﬁed, including any
speciﬁc morphological features of GC in the setting of other
hereditary cancer syndromes. Majewski et al23 reported a family
with a germline CTNNA1 mutation presenting with multiple
DGC cases and intramucosal signet ring cells.
Immunohistochemistry of α-E-catenin showed absent staining in
the signet ring cells, while tumours from 10 other HDGC pedi-
grees without CDH1 and CTNNA1 mutation stained positively.
Two additional families have recently been described, one of
which shared an immunohistochemical phenotype with loss of
α-catenin and cytoplasmic rather than membranous
E-cadherin.24 This ﬁnding suggests either that the pathogenicity
of CTNNA1 mutations may be mediated through loss of
E-cadherin function or that the cancer-initiating potential of
CDH1 mutations is imparted through α-catenin-associated path-
ways. More research is needed to understand the role and muta-
tion detection rate of CTNNA1 mutations.
POSTSURGICAL CARE AND NUTRITION
Postoperative care
The psychological, physiological and metabolic impact of a total
gastrectomy should not be underestimated. The physical impact
of a gastrectomy is difﬁcult to predict for any individual, but
there is an expectation that most patients will return to a full
and active life after their operation. Reassuringly, global
quality-of-life scores recover to presurgery levels at around
12 months postoperatively; however, problems with eating,
abdominal pain and reduced body image persist beyond this
time.101
Enhanced postgastrectomy recovery programmes are now well
established. These programmes may include preoperative carbo-
hydrate loading, preferably the avoidance of a nasogastric tube or
abdominal drain, early mobilisation with good analgesia (epi-
dural or local anaesthetic wound catheters), resume oral intake
within 3–5 days and discharge from hospital within 7–10 days.
In addition, patients often require considerable support during
the ﬁrst 12 months after surgery. Implementation of this support
will depend upon the local healthcare services and the distances
required for patients to attend the centre. Specialist nurses and
dieticians should maintain regular contact by telephone and the
use of modern video-conferencing should be encouraged.
Collection of clinical data in a national registry allows patients, if
they choose, to contribute to HDGC syndrome research.
There are different issues related to mastectomy (prophylactic
or otherwise), a second major surgery with a signiﬁcant recovery
period. Mastectomy has a different impact concerning self-
image, self-esteem, physical appearance and loss of feminine
identity. Therefore, a team including a dietician, physiotherapist
and psychologist should be available for optimal physical and
socio-emotional recovery during postoperative care of both gas-
trectomy and mastectomy.
Nutrition
The main adjustments with regard to diet and nutrition postgas-
trectomy have to do with (1) maintaining weight; (2) ensuring
adequate ﬂuid, nutritional and caloric intake; and (3) behav-
ioural modiﬁcations surrounding eating. Experienced dieticians
focus on nutritional problems and strategies for maintaining
weight after surgery, while patients focus on lifestyle changes.
Patients are often discouraged by weight loss. The median
weight loss 1 year postsurgery is 10 kg.101 This means that
patients who are underweight preoperatively or who have a
history of eating disorders need very careful counselling and
support. Anatomical changes can make the act of eating difﬁ-
cult, and patients may become disappointed by these hurdles.
This can further complicate weight management with the psy-
chological burden of eating. In the early stages of recovery,
intentional eating, drinking, management of symptoms and
resting can quickly become draining. It is important for patients
to have realistic expectations for their progress and improve-
ment over time. Common postsurgical symptoms, risks and
treatment options are listed in table 2.
Following a prophylactic gastrectomy, patients initially have
to eat frequent small meals. Eating too much and/or too quickly
will cause abdominal pain. Dumping syndrome is a group of
Table 2 Postgastrectomy symptoms and treatment options
Symptoms Treatment
Early dumping (15–30 min after eating) Modification of diet and eating habits
Late dumping (1.5–3 h after eating) Modification of diet and eating habits
Lactose intolerance Diet modifications, supplementation with lactase enzymes
Fat malabsorption Pancreatic enzyme replacement may be necessary, especially fats and fat-soluble vitamins such as vitamin D 102
Small bowel bacterial overgrowth/blind loop
syndrome
Antibiotics, sometimes surgery
Dysphagia and anastomotic strictures Modification of eating habits (more deliberate mastication and smaller bites)
Upper endoscopy with balloon dilatation to widen the stricture
Sometimes postsurgical intervention
Changing response to usage of alcohol Alertness physician and patient
Absorption of medication can be affected Alertness physician and patient
Monitoring deficiencies of iron, vitamin B12, folate
and trace elements
Supplementing of vitamin B12 and/or folate.103–105 Intravenous iron infusions may become necessary if individuals are
unable to tolerate iron orally, unable to absorb sufficient iron through the gut, or require rapid increase in iron levels
to avoid other health complications or a blood transfusion
Hypocalcaemia, osteoporosis, osteopenia and
osteomalacia
Calcium and vitamin D are required to reduce risk of bone disease. When levels cannot be maintained through
consumption of calcium-rich foods, supplements such as vitamin D, calcium carbonate, calcium phosphate and calcium
citrate can be used.
Calcium citrate does not require acid for absorption, making it a strong choice of supplement106
Bile reflux (due to the absence of the
gastroesophageal valve)
Type of surgical procedure (appropriate length of the Roux limb) reduces the occurrence of bile reflux
Use of wedge pillow for sleeping
Limiting oral intake to 2–3 h before going to bed
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symptoms commonly experienced as a result of altered gut
anatomy following gastrectomy, caused by rapid entry of food
into the small intestine at an earlier stage of digestion. This
leads to a shift of ﬂuid from the bloodstream to the small intes-
tine to aid in digestion, and may lead to cardiovascular and
abdominal symptoms. Late dumping is caused by a rapid rise
and subsequent decrease in blood sugar levels by delayed insulin
secretion. After gastrectomy, food moves rapidly and directly
into the small intestine, where it digests faster. Also, the pan-
creas produces more insulin in a short time. This excessive
insulin production allows for a rapid decrease in the blood
sugar.107 These symptoms may be more common in the imme-
diate postoperative period and often subside over time.
Dumping syndrome can be minimised or eliminated through
dietary choices and modiﬁed eating habits; adequate adjust-
ments are unique from patient to patient. With time, however,
these symptoms tend to improve.101 Other problems may
include lactose intolerance, steatorrhoea, small bowel bacterial
overgrowth, anastomotic strictures and postprandial full-
ness.108 109 Patients should be warned that their tolerance to
alcohol will reduce after gastrectomy and that absorption of
some medications can be affected.
As a result of malabsorption, patients with postgastrectomy
are at risk for nutritional deﬁciencies. Monitoring of nutritional
levels in postsurgical follow-up is essential as deﬁciencies
increase risk for other symptoms and health concerns. All
patients require lifelong vitamin B12 supplementation (either
oral, subcutaneous or intramuscularly) to correct identiﬁed deﬁ-
ciencies, and close monitoring for conditions such as iron deﬁ-
ciency, anaemia, hypocalcaemia, osteoporosis and trace element
deﬁciencies. Many dieticians recommend patients to take a daily
multivitamin preparation with iron; however, it remains import-
ant to monitor iron levels since absorption will change after gas-
trectomy. While these are the most commonly reported
symptoms, attention should be paid to any signiﬁcant and pro-
longed changes, such as hair loss or extreme fatigue. These
symptoms and changes away from the patient’s baseline may be
indicative of nutritional deﬁciencies, which may need to be
identiﬁed and treated.
Patients should consult a dietician prior to surgery as an
awareness of baseline nutritional status and dietary habits will
beneﬁt the patient in postsurgical nutrition, diet and weight
management. While there are some basic dietary principles that
apply to most patients with gastrectomy, there are no absolute
rules. Each patient’s recovery is unique, from food and quantity
tolerances, to comfortable eating habits. Variability is observed
between patients, but also for individual patients during the
course of their recovery. The most notable changes occur within
the ﬁrst year; however, deﬁciencies should be carefully followed
since they can also develop over years. Patients are encouraged
to continue to experiment and discover what is best suited to
their needs and tolerances.
Future research: nutrition postgastrectomy
Further studies are needed to elucidate the relationship in
patients with postgastrectomy between diet, nutrition, drug
absorption, changes in body composition and the direct impact
on quality of life, both in the short term and long term.
PATIENT ADVOCACY AND THE NEXT STEPS IN PATIENT
CARE AND HDGC RESEARCH
In patients’ experience, the process that HDGC families go
through to ﬁnd local medical care providers with experience
with HDGC is frustrating. Faced with the lack of universal
expertise, patients and advocacy groups have started working
together to locate local care providers with expertise or facilitate
connecting local care providers with experts at globally recog-
nised multidisciplinary centres of excellence. Medical expertise
in HDGC has to continue to grow, and this expertise has to be
communicated within the medical community, such that support
structures for patients with HDGC will become more easily
accessible and established within existing medical systems.
Given the rare nature of HDGC, there is currently no singular
global expertise portal for genetic counselling, psychosocial
support, gastroenterology, surgery, pathology and postsurgery
follow-up for HDGC families. The geography of existing
expertise centres does not nearly cover broadly enough the
areas where these resources are needed. With the emerging
trend towards telemedicine, and the development of various
patient advocacy groups, notably ‘No Stomach For Cancer’,110
‘DeGregorio Family Foundation for Stomach and Esophageal
Cancer Research’111 in the USA and ‘Stichting CDH1’112 in the
Netherlands, we see the potential for collaboration between
patients, medical professionals and patient advocacy groups to
the end of empowering patients by directing and connecting
them with the appropriate resources and expert opinions.
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